外周血造血干细胞移植治疗恶性血液病21例报告  

Peripheral blood hematopoietic stem cell transplantation in twenty-one patients with malignant hematological disease

作　　者：王景昌[1] 赵红娟[1] 党社明 鲁会卿[1] 王雅琳[1] 赵双平[1] 金宝艳 

机构地区：[1]解放军第三医院血液科,陕西宝鸡721004

出　　处：《西北国防医学杂志》2011年第2期106-108,共3页Medical Journal of National Defending Forces in Northwest China

摘　　要：目的:观察外周血造血干细胞移植(PBHSCT)治疗恶性血液病的疗效和并发症。方法:21例恶性血液病中8例行自体PBHSCT(auto-PBHSCT),13例行异基因PBHSCT(allo-PBHSCT)。结果:21例全部获得造血重建,随访7～42月,10例(47.6%)存活,其中:auto-PBHSCT 5例,allo-PBHSCT5例。11例(52.4%)死亡,其中:auto-PBHSCT:3例复发死亡;allo-PBHSCT:5例复发死亡,2例移植相关死亡,1例死于第二肿瘤。结论:PBHSCT是治疗恶性血液病的有效方法,但如何有效减少复发、提高长期无病生存率需要进一步研究。Objective：To investigate the clinical efficacy and complication of peripheral hematopoietic blood stem cell transplantation（PBHSCT） in 21 patients with malignant hematological disease.Methods： Twenty-one patients with malignant hematological disease received PBHSCT,including 8 cases of auto-PBHSCT,13 cases of allo-PBHSCT.Results：The median follow-up duration was 7 to 42 months.Ten cases（47.6%） of all were alive,including 5 cases of auto-PBHSCT,5 cases of allo-PBHSCT.Eleven patients（52.4%） died,including 3 cases of auto-PBHSCT died from relapse,5 cases of allo-PBHSCT died from relapse,and 2 cases died from transplantation related mortality（TRM）,and 1 case died from the second tumor.Conclusion：PBHSCT has a good efficacy in the treatment of malignant hematological disease and can enhance the disease-free survival.

关 键 词：恶性血液病 外周血造血干细胞移植 报告 

分 类 号：R733[医药卫生—肿瘤]